AZD 7624

Drug Profile

AZD 7624

Alternative Names: AZD-7624

Latest Information Update: 20 May 2017

Price : $50

At a glance

  • Originator AstraZeneca
  • Class Antiasthmatics; Small molecules
  • Mechanism of Action P38 mitogen-activated protein kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Chronic obstructive pulmonary disease

Most Recent Events

  • 30 Sep 2016 Discontinued - Phase-I for Chronic obstructive pulmonary disease (In volunteers) in United Kingdom (Inhalation) because of unfavourable safety and efficacy results (AstraZeneca pipeline, November 2016; AstraZeneca quarterly report, November 2016)
  • 30 Sep 2016 Discontinued - Phase-II for Chronic obstructive pulmonary disease in Netherlands, Argentina, Chile, Peru, South Africa, USA (Inhalation) because of unfavourable safety and efficacy results (AstraZeneca pipeline, November 2016; AstraZeneca quarterly report, November 2016)
  • 16 Jul 2016 No recent reports of development identified for phase-I development in Chronic-obstructive-pulmonary-disease(In volunteers) in United Kingdom (Inhalation, Aerosol)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top